Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221006, China.
Department of Epidemiology & Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, 230032, China.
Future Oncol. 2024;20(28):2071-2081. doi: 10.1080/14796694.2024.2376512. Epub 2024 Jul 23.
This multicenter retrospective study aimed to develop a novel prognostic system for extranodal natural killer/T-cell lymphoma (ENKTL) patients in the era of pegaspargase/L-asparaginase. A total of 844 newly diagnosed ENKTL patients were included. Multivariable analysis confirmed that Eastern Cooperative Oncology Group performance status, lactate dehydrogenase, Chinese Southwest Oncology Group and Asia Lymphoma Study Group ENKTL (CA) system, and albumin were independent prognostic factors. By rounding up the hazard ratios from four significant variables, a maximum of 7 points were assigned. The model of Huaihai Lymphoma Working Group-Natural killer/T-cell Lymphoma prognostic index (NPI) was identified with four risk groups and the 5-year overall survival was 88.2, 66.7, 54.3 and 30.5%, respectively. Huaihai Lymphoma Working Group-NPI provides a feasible stratification system for patients with ENKTL in the era of pegaspargase/L-asparaginase.
这项多中心回顾性研究旨在为培门冬酶/左旋门冬酰胺酶时代的结外自然杀伤/T 细胞淋巴瘤（ENKTL）患者开发一种新的预后系统。共纳入 844 例新诊断的 ENKTL 患者。多变量分析证实，东部肿瘤协作组表现状态、乳酸脱氢酶、中国西南肿瘤协作组和亚洲淋巴瘤研究组 ENKTL（CA）系统以及白蛋白是独立的预后因素。通过四 个显著变量的风险比取整，最高可分配 7 分。确定了淮海淋巴瘤工作组-自然杀伤/T 细胞淋巴瘤预后指数（NPI）模型，分为四个风险组，5 年总生存率分别为 88.2%、66.7%、54.3%和 30.5%。在培门冬酶/左旋门冬酰胺酶时代，淮海淋巴瘤工作组-NPI 为 ENKTL 患者提供了一种可行的分层系统。
